|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.88 CNY | +0.66% |
|
+0.48% | -8.59% |
BEIJING, Jan 20 (Reuters) - Shanghai Fosun Pharmaceutical said on Friday that it and Henan Genuine Biotech will cooperate with multiple companies to expand production of the COVID treatment Azvudine.
Demand for the treatment has surged since the government dismantled its zero-COVID restrictions, the company said, adding that full production would continue over the Lunar New Year holidays. (Reporting by Beijing Newsroom; editing by Jason Neely)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.59% | 7.54B | |
| +25.25% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.25% | 233B | |
| +5.34% | 201B | |
| -10.22% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 
